中东和非洲临床试验成像市场，按产品和服务（服务和软件）、方式（计算机断层扫描、磁共振成像、超声心动图、核医学、正电子发射断层扫描、X 射线、超声波、光学相干断层扫描等）、应用（肿瘤学、神经病学、内分泌学、心脏病学、皮肤病学、血液学等）、最终用户（制药和生物技术公司、合同研究组织、医疗器械制造商、学术和政府研究机构等）、分销商（直销和招标销售）划分 - 行业趋势和预测到 2029 年。
中东和非洲临床试验成像市场分析和见解
成像技术的需求不断增加，老年人口增加导致慢性病患病率上升，以及市场参与者采取的产品发布、进步、收购和协议等战略举措，都是预计推动市场增长的因素。
然而，成像设备的不适当和不利的报销情形以及临床试验成像仪器缺乏明确的标准预计会抑制市场的增长。
用于诊断和治疗慢性疾病的临床试验成像技术不断进步，预计将推动市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，中东和非洲临床试验成像市场将以 6.5% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 (可定制至 2019-2014) |
|
定量单位 |
收入（百万美元）和定价（美元） |
|
涵盖的领域 |
按产品和服务（服务和软件）、模式（计算机断层扫描、磁共振成像、超声心动图、核医学、正电子发射断层扫描、X 射线、超声波、光学相干断层扫描等）、应用（肿瘤学、神经病学、内分泌学、心脏病学、皮肤病学、血液学等）、最终用户（制药和生物技术公司、合同研究组织、医疗器械制造商、学术和政府研究机构等）、分销商（直销和招标销售） |
|
覆盖国家 |
南非、沙特阿拉伯、中东和非洲其他地区 |
|
涵盖的市场参与者 |
Resonance Health Analytical Services、Paraxel International Corporation 和 WIRB-Copernicus Group |
市场定义
临床试验是开发新药的过程。它旨在研究潜在的治疗及其对人类的影响。在新药商业化之前，会进行广泛的临床试验以识别有希望的化合物，并进行安全测试以确定可能的风险。
在临床试验中，医学成像在获得更准确、更有效的结果方面发挥着重要作用。可以使用不同的成像技术来阐明和展示药物的机械作用。临床试验成像是通过创建身体内部图像表示来进行临床分析和医疗干预的过程。它有几种不同的技术，用于观察人体以监测、治疗和诊断医疗状况。
在不久的将来，与药物发现临床试验成像相关的重要决策将由不仅了解活检，而且还能使用临床试验成像工具及其发布的知识来制定假设和确定质量目标的个人做出
中东和非洲临床试验成像市场动态
驱动程序
- 研发支出不断增加
影像和制药公司不断投资研发，为客户提供临床试验影像创新服务，并提升其市场占有率。医学影像在临床开发中发挥着重要作用。尽管医学影像行业由于新技术在市场上的实施而处于不断波动的状态，但制药和影像行业仍在不断增长。这归因于对医学影像公司的投资增加、并购以及采用影像技术创新来支持医疗器械的临床试验。制药和生物技术公司增加研发支出正在推动市场增长。
这促进了生物制药行业组织新产品和高研究导向项目的开发，以及对人类基因组研究的高度偏好。研发支出的增加也促进了治疗慢性疾病的新药和新疗法的开发，从而促进了市场的增长。这有助于制药和生物技术公司在成像临床试验类别中开发新技术，因此，研发支出的增加预计将推动市场增长。
- 合同研究组织 (CRO) 数量不断增加
合同研究组织 (CRO) 是一家以药物和医疗器械外包药物研究服务的形式为成像和制药行业提供临床试验和其他研究服务的组织。CRO 帮助成像和制药行业进行药物开发流程，以降低成本，并通过使用临床试验成像和其他流程启动临床试验流程，以开发针对特定疾病领域的药物，以弥补内部研究团队在药物和临床研究方面的能力差距。
大量 CRO 参与监测药物开发过程，例如 PAREXEL（美国）、PRA Health Sciences（美国）、Labcorp（美国）、PPD（美国）、Syneos Health（美国）、ICON plc（爱尔兰）、Envigo（英国）、Charles River（美国）和 SGS（瑞士）等。这些 CRO 致力于为成像和制药行业提供临床试验和其他研究服务支持。预计 CRO 数量的增加将推动市场增长。
机会
- 医疗支出增加
随着各国人民的可支配收入不断提高，全球医疗支出也随之增加。此外，为满足人口需求，政府机构和医疗机构正通过加快医疗支出来发挥主动作用。
例如，
- 美国国家卫生支出账户（NHEA）发布报告称，2019年美国医疗支出增长了4.6%。根据美国医疗保险中心（CMS）报告的数据，美国总人口医疗支出约为3.80万亿美元，而美国的健康支出占GDP的17.7%。
医疗支出的增长也有利于经济和医疗保健领域的进一步增长，而且它的主要成果是，它显著影响了市场上更好、更先进的医疗产品的开发。因此，预计医疗支出的激增将为市场创造更大的机会。
- 市场参与者的战略举措
由于研发水平的提高以及临床试验成像市场的增长以及对创新药物的需求，市场对临床试验成像的需求正在增加。因此，顶级市场参与者实施了一项新战略，通过开发新产品并与其他市场参与者合作来改善业务运营和盈利能力。
例如，
- 2020 年 2 月，ICON plc 收购了欧洲医疗器械 CRO、报销和监管咨询公司 MedPass International。据报道，此次收购有助于 ICON 在欧洲扩大医疗器械和诊断研究服务。
市场参与者的这些战略举措，包括收购、会议和重点细分产品发布，正在帮助他们发展和改善公司的产品组合，最终带来更多收入。因此，市场参与者的这些战略举措可能成为市场增长的机会。
限制/挑战
- 高风险辐射致病
在临床医学成像中，辐射会被人体吸收，从而损害患者体内的分子结构。高剂量的辐射会影响人体细胞，包括脱发、皮肤烧伤和癌症发病率增加。在 CT 扫描中接受 10 mSv 辐射剂量后，患上致命癌症的风险估计为 2000 分之一。
例如，
- 根据美国放射学会 (RSNA) 的数据，美国 1% 至 2% 的癌症是由 CT 扫描引起的，美国癌症协会将 CT 扫描和 X 射线确定为乳腺癌、脑癌和其他癌症的原因之一
- 据美国疾病控制与预防中心称，暴露于高剂量辐射会导致急性辐射综合症。人体吸收的辐射量称为辐射剂量。
发生的高风险辐射会降低临床试验成像设备的使用和销售，从而影响参与该市场的制造商的信誉。因此，预计高风险辐射致病将抑制市场增长。
- 严格的监管政策
医疗保健行业受到广泛而复杂的法律、规则和法规体系的监管。
例如，
- 2018 年 4 月，美国 FDA 发布了最新的《临床试验影像终点流程标准指南》，其中包括临床试验中获得的影像数据的质量
- 生物科技和制药行业需要首先获得 FDA 的药物开发批准。在开始临床研究之前，他们必须向 FDA 提交新药临床试验 (IND) 申请。
COVID-19 对中东和非洲临床试验成像市场的影响
诊断成像服务耗时且复杂，因为需要制定严格的感染控制和预防措施来控制传播风险并保护医护人员。因此，是否对疑似患者或 COVID-19 阳性患者进行成像取决于其对患者状况改善的影响。
例如，
- 据《美国放射学会杂志》发表的一封信称，加州大学洛杉矶分校 (UCLA) 和南加州大学 (USC) 的研究人员正在开发磁共振成像 (MRI) 服，这种服可以大大降低放射科医生、操作员和患者的传播风险。由于一般 X 射线和计算机断层扫描成像程序是 COVID-19 初步和后续调查的主要方式，因此人们认为这些程序的工作量有所增加。不过，在研究期间，个人防护装备供应充足。因此，除 COVID-19 之外的其他疾病的医疗服务有限，对全球执行的医学成像程序数量产生了负面影响。
最新动态
- 2022 年 1 月，Clario 与放射性药物生产和正电子发射断层扫描 (PET) 收购公司 XingImaging 合作，在中国开展 PET 成像临床试验，以测试新型疗法。此次合作旨在共享 Clario 和 XingImaging 的联合资源和神经科学专家，以加快在中国开展临床试验和药物研发。
- 2021 年 11 月，Clario 成立。ERT 和 Bioclinica 合并成立 Clario。新公司的成立带来了临床成像软件和服务的分销以及销售额的上升。
中东和非洲临床试验成像市场范围
中东和非洲临床试验成像市场根据产品和服务、模式、应用、最终用户和分销商分为五个部分。这些部分之间的增长将帮助您分析行业中增长微弱的部分，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
產品與服務
- 服务
- 软件
根据产品和服务，市场分为服务和软件。
情态
- 计算机断层扫描
- 磁共振成像
- 超声心动图
- 核医学
- 正电子发射断层扫描
- X 射线
- 超声波
- 光学相干断层扫描
- 其他的
根据模式，市场分为计算机断层扫描、磁共振成像、超声心动图、核医学、正电子发射断层扫描、X射线、超声波、光学相干断层扫描等。
应用
- 肿瘤学
- 神经病学
- 心脏病学
- 内分泌学
- 皮肤科
- 血液学
- 其他的
根据应用，市场分为肿瘤学、神经病学、心脏病学、内分泌学、皮肤病学、血液学和其他。
最终用户
- 合同研究组织
- 制药及生物技术公司
- 医疗器械制造商
- 学术和政府研究机构
- 其他的
根据最终用户，市场分为合同研究组织、制药和生物技术公司、医疗设备制造商、学术和政府研究机构等。
分销商
- 直销
- 招标销售
根据分销商，市场分为直销和招标销售。
中东和非洲临床试验成像市场区域分析/见解
对中东和非洲临床试验成像市场进行了分析，并按上述地区、产品和服务、方式、应用、最终用户和分销商提供了市场规模洞察和趋势。
本市场报告涵盖的国家包括南非、沙特阿拉伯、中东和非洲其他地区。由于人工智能 (AI) 在沙特阿拉伯医学成像领域发挥着重要作用，沙特阿拉伯预计将占据市场主导地位。人工智能在放射学中起着至关重要的作用；确保放射科医生和放射技师至少对该技术有最低限度的了解非常重要。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场法规变化。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了中东和非洲品牌的存在和可用性，以及由于来自本地和国内品牌的激烈或稀少的竞争对销售渠道的影响而面临的挑战。
竞争格局和中东和非洲临床试验成像市场份额分析
中东和非洲临床试验成像市场竞争格局提供了有关竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、中东和非洲的业务、生产基地和设施、生产能力、公司的优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对中东和非洲临床试验成像市场的关注有关。
市场上的一些主要参与者包括 Navitas Life Sciences、Resonance Health Analytical Services、BioTelemetry、飞利浦公司 (Philips Company)、IXICO plc、ICON plc、anagram 4 clinical trials、Quotient Sciences、WORLDCARE CLINICAL、Clario、Paraxel International Corporation、Median Technologies、Perspectum、Calyx、WIRB-Copernicus Group 和 Invicro.LLC 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS AND SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING R&D EXPENDITURE
6.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS)
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.1.4 GROWTH IN THE PHARMACEUTICAL AND IMAGING INDUSTRIES
6.2 RESTRAINTS
6.2.1 HIGH-RISK RADIATION CAUSING DISEASES
6.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS
6.3.3 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS
6.4 CHALLENGES
6.4.1 STRICT REGULATORY POLICIES
6.4.2 COST OF CLINICAL TRIALS
7 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES
7.1 OVERVIEW
7.2 SERVICES
7.2.1 OPERATIONAL IMAGING SERVICES
7.2.2 READ ANALYSIS SERVICES
7.2.3 TRIAL DESIGN CONSULTING SERVICES
7.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES
7.3 SOFTWARE
8 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY
8.1 OVERVIEW
8.2 COMPUTED TOMOGRAPHY
8.3 MAGENTIC RESONANCE IMAGING
8.4 ECHOCARDIOGRAPHY
8.5 NUCLEAR MEDICINE
8.6 POSITRON EMISSION TOMOGRAPHY
8.7 X-RAY
8.8 ULTRASOUND
8.9 OPTICAL COHERENCE TOMOGRAPHY
8.1 OTHERS
9 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 X-RAY
9.2.2 ULTRASOUND
9.2.3 COMPUTED TOMOGRAPHY
9.2.4 MAGNETIC RESONANCE IMAGING
9.2.5 NUCLEAR MEDICINE
9.2.6 POSITRON EMISSION TOMOGRAPHY
9.2.7 OPTICAL COHERENCE TOMOGRAPHY
9.2.8 ECHOCARDIOGRAPHY
9.2.9 OTHERS
9.3 NEUROLOGY
9.3.1 COMPUTED TOMOGRAPHY
9.3.2 MAGNETIC RESONANCE IMAGING
9.3.3 POSITRON EMISSION TOMOGRAPHY
9.3.4 NUCLEAR MEDICINE
9.3.5 X-RAY
9.3.6 ULTRASOUND
9.3.7 OPTICAL COHERENCE TOMOGRAPHY
9.3.8 ECHOCARDIOGRAPHY
9.3.9 OTHERS
9.4 CARDIOLOGY
9.4.1 ECHOCARDIOGRAPHY
9.4.2 MAGNETIC RESONANCE IMAGING
9.4.3 COMPUTED TOMOGRAPHY
9.4.4 POSITRON EMISSION TOMOGRAPHY
9.4.5 NUCLEAR MEDICINE
9.4.6 X-RAY
9.4.7 ULTRASOUND
9.4.8 OPTICAL COHERENCE TOMOGRAPHY
9.4.9 OTHERS
9.5 ENDOCRINOLOGY
9.5.1 COMPUTED TOMOGRAPHY
9.5.2 MAGNETIC RESONANCE IMAGING
9.5.3 ECHOCARDIOGRAPHY
9.5.4 POSITRON EMISSION TOMOGRAPHY
9.5.5 NUCLEAR MEDICINE
9.5.6 X-RAY
9.5.7 ULTRASOUND
9.5.8 OPTICAL COHERENCE TOMOGRAPHY
9.5.9 OTHERS
9.6 DERMATOLOGY
9.6.1 ULTRASOUND
9.6.2 X-RAY
9.6.3 MAGNETIC RESONANCE IMAGING
9.6.4 COMPUTED TOMOGRAPHY
9.6.5 OPTICAL COHERENCE TOMOGRAPHY
9.6.6 POSITRON EMISSION TOMOGRAPHY
9.6.7 NUCLEAR MEDICINE
9.6.8 ECHOCARDIOGRAPHY
9.6.9 OTHERS
9.7 HEMATOLOGY
9.7.1 ULTRASOUND
9.7.2 COMPUTED TOMOGRAPHY
9.7.3 MAGNETIC RESONANCE IMAGING
9.7.4 X-RAY
9.7.5 POSITRON EMISSION TOMOGRAPHY
9.7.6 NUCLEAR MEDICINE
9.7.7 OPTICAL COHERENCE TOMOGRAPHY
9.7.8 ECHOCARDIOGRAPHY
9.7.9 OTHERS
9.8 OTHERS
10 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.4 MEDICAL DEVICE MANUFACTURERS
10.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
10.6 OTHERS
11 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR
11.1 OVERVIEW
11.2 DIRECT SALES
11.3 TENDER SALES
12 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY REGION
12.1 MIDDLE EAST AND AFRICA
12.1.1 SAUDI ARABIA
12.1.2 SOUTH AFRICA
12.1.3 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 NAVITAS LIFE SCIENCES
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 RESONANCE HEALTH ANALYTICAL SERVICES
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 CLARIO
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 PARAXEL
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 BIOTELEMETRY, A PHILIPS COMPANY
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ICON PLC
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 MEDIAN TECHNOLOGIES
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 PERSPECTUM
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ANAGRAM 4 CLINICAL TRIALS
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 CALYX
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 IMAGE CORE LAB
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 INVICRO. LLC. (A SUBSIDIARY OF KONICA MINOLTA)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 IXICO PLC
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 QUOTIENT SCIENCES
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 RADIANT SAGE LLC
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 WIRB-COPERNICUS GROUP
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 WORLDCARE CLINICAL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3
TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES
TABLE 3 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION,2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 53 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 54 SAUDI ARABIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 55 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 56 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 SAUDI ARABIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 SAUDI ARABIA NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 66 SOUTH AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 67 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 68 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 69 SOUTH AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 SOUTH AFRICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 SOUTH AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 SOUTH AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 SOUTH AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 SOUTH AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 77 REST OF MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
FIGURE 11 THE INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION AND RISING R&D EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET
FIGURE 14 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN USD MILLION)
FIGURE 15 THE MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 16 THE FUNCTION OF CRO
FIGURE 17 ESTIMATED NEW CANCER CASES, 2022
FIGURE 18 VALUE OF THE PHARMACEUTICAL SECTOR, WORLDWIDE, 2021 BY COUNTRY (IN MILLION U.S. DOLLARS)
FIGURE 19 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2021
FIGURE 20 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2022-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2021
FIGURE 24 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2022-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2021
FIGURE 28 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, 2021
FIGURE 32 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2021
FIGURE 36 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2022-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2021)
FIGURE 40 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021)
FIGURE 41 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2022-2029)
FIGURE 44 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2021 (%)]
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
